Xiang Huang1, Rong Zhang, Liang-Fu Zhou. 1. Department of Neurosurgery, Huashan Hospital, and Department of Neurosurgery, Shanghai Medical College, Fudan University, Shanghai 200040, PR China.
Abstract
OBJECTIVE: The purpose of this paper is toexplore the clinical features, treatment and prognosis of intracranial immature teratomas. METHODS: The clinical data, serum levels of tumor markers, treatment regimens and prognosis of 15 patients with intracranial immature teratomas were reviewed retrospectively. RESULTS: In patients whose plasma alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (beta-HCG) were determined, AFP and beta-HCG were elevated in 57.1 and 16.7% of the cases, respectively. All patients received surgical treatment. The tumor was totally removed in 12 cases, subtotally in 2, and partially in 1 case. After surgery, of the 15 patients, 9 received radiotherapy, 4 gamma knife surgery and 7 chemotherapy. Thirteen patients were followed up. Compared to the common 5-year survival rate of 40%, in patients who received gamma knife surgery, the 5-year survival rate after surgery was 100%, which is better than the 5-year survival rate of patients who did not receive gamma knife surgery (p = 0.0049). Postoperative radiotherapy and chemical therapy had no significant impact on the 5-year survival rate (p > 0.05). CONCLUSIONS: The prognosis of intracranial immature teratomas is poor. The detection of their clinical manifestation, the analysis of imaging features and the serum levels of tumor markers are helpful in diagnosing intracranial teratomas. The total removal of the tumor is important to cure the disease. We did not see a difference in outcome between patients who received postoperative chemotherapy or radiotherapy and those who did not. Regular follow-up MRI examinations are necessary so that the conditions of the patients can be closely monitored. If a patient has residual or recurrent tumor after surgery, gamma knife surgery can be effective. Copyright 2009 S. Karger AG, Basel.
OBJECTIVE: The purpose of this paper is toexplore the clinical features, treatment and prognosis of intracranial immature teratomas. METHODS: The clinical data, serum levels of tumor markers, treatment regimens and prognosis of 15 patients with intracranial immature teratomas were reviewed retrospectively. RESULTS: In patients whose plasma alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (beta-HCG) were determined, AFP and beta-HCG were elevated in 57.1 and 16.7% of the cases, respectively. All patients received surgical treatment. The tumor was totally removed in 12 cases, subtotally in 2, and partially in 1 case. After surgery, of the 15 patients, 9 received radiotherapy, 4 gamma knife surgery and 7 chemotherapy. Thirteen patients were followed up. Compared to the common 5-year survival rate of 40%, in patients who received gamma knife surgery, the 5-year survival rate after surgery was 100%, which is better than the 5-year survival rate of patients who did not receive gamma knife surgery (p = 0.0049). Postoperative radiotherapy and chemical therapy had no significant impact on the 5-year survival rate (p > 0.05). CONCLUSIONS: The prognosis of intracranial immature teratomas is poor. The detection of their clinical manifestation, the analysis of imaging features and the serum levels of tumor markers are helpful in diagnosing intracranial teratomas. The total removal of the tumor is important to cure the disease. We did not see a difference in outcome between patients who received postoperative chemotherapy or radiotherapy and those who did not. Regular follow-up MRI examinations are necessary so that the conditions of the patients can be closely monitored. If a patient has residual or recurrent tumor after surgery, gamma knife surgery can be effective. Copyright 2009 S. Karger AG, Basel.
Authors: Steven Denyer; Abhiraj D Bhimani; Shashank N Patil; Andrew Mudreac; Mandana Behbahani; Ankit I Mehta Journal: J Cancer Res Clin Oncol Date: 2019-11-19 Impact factor: 4.553
Authors: Seung-Bin Woo; Chang-Young Lee; Chang-Hyun Kim; Young San Ko; El Kim; Ye Jee Shim; Sang Pyo Kim; Sae Min Kwon Journal: Brain Tumor Res Treat Date: 2022-04